Gilead price target raised to $132 from $115 at Oppenheimer
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
HHS increasing scrutiny of vaccines under RFK Jr., WSJ reports
The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...
News241h
The Global Fund will roll out the twice-yearly anti-HIV jab – with or without Pepfar
The Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
gut.bmj18h
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis
PG declares that he has received research funding from Mallinckrodt, Grifols and Gilead. He has participated on advisory boards for Novartis, Promethera, Sequana, Gilead and Martin Pharmaceuticals.